​

Verve Therapeutics (VERV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VERV Stock Forecast

Verve Therapeutics (VERV) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $14.50, with a high of $15.00 and a low of $14.00. This represents a 215.90% increase from the last price of $4.59.

- $4 $8 $12 $16 $20 High: $15 Avg: $14.5 Low: $14 Last Closed Price: $4.59

VERV Stock Rating

Verve Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (75.00%), 2 Hold (16.67%), 1 Sell (8.33%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 2 9 Strong Sell Sell Hold Buy Strong Buy

VERV Price Target Upside V Benchmarks

TypeNameUpside
StockVerve Therapeutics215.90%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$15.00$14.50
Last Closing Price$4.59$4.59$4.59
Upside/Downside-226.80%215.90%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25352--10
Mar, 25352--10
Feb, 25342--9
Jan, 25352--10
Dec, 24352--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 04, 2025RBC Capital$15.00$6.12145.10%226.80%
Nov 06, 2024Mitchell KapoorH.C. Wainwright$14.00$6.32121.52%205.01%
Apr 03, 2024Kostas BiliourisBMO Capital$30.00$8.57250.06%553.59%
Dec 15, 2022Goldman Sachs$13.00$22.61-42.50%183.22%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2025GuggenheimBuyBuyhold
Feb 28, 2025H.C. WainwrightBuyBuyhold
Nov 06, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024RBC CapitalOutperformOutperformhold
May 09, 2024JefferiesBuyBuyhold
Apr 08, 2024H.C. WainwrightBuyinitialise
Apr 03, 2024BMO CapitalOutperformOutperformhold
Apr 02, 2024RBC CapitalOutperformOutperformhold
Feb 01, 2023Cantor FitzgeraldNeutralinitialise
Dec 15, 2022Goldman SachsSellinitialise

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.91$-3.12$-2.35----
Avg Forecast$-2.94$-3.16$-2.43$-2.81$-2.91$-2.90$-3.38
High Forecast$-1.81$-3.00$-2.26$-2.52$-2.22$-2.15$-1.51
Low Forecast$-3.98$-3.51$-2.61$-3.38$-3.82$-3.69$-4.61
Surprise %-1.02%-1.27%-3.29%----

Revenue Forecast

$0 $9M $18M $27M $36M $45M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.94M$11.76M$32.33M----
Avg Forecast$1.21M$11.15M$23.82M$14.57M$9.98M$34.00M$13.60M
High Forecast$1.53M$14.45M$29.94M$18.65M$12.78M$43.53M$17.41M
Low Forecast$846.97K$8.57M$19.46M$8.35M$5.72M$19.50M$7.80M
Surprise %61.08%5.47%35.71%----

Net Income Forecast

$-300M $-250M $-200M $-150M $-100M $-50M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-157.39M$-200.07M$-198.71M----
Avg Forecast$-188.89M$-200.07M$-156.29M$-189.29M$-193.76M$-187.18M$-216.91M
High Forecast$-115.93M$-192.40M$-145.33M$-161.61M$-142.57M$-137.82M$-96.62M
Low Forecast$-255.55M$-225.08M$-167.25M$-216.97M$-244.96M$-236.54M$-295.92M
Surprise %-16.68%-27.14%----

VERV Forecast FAQ

Is Verve Therapeutics stock a buy?

Verve Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Verve Therapeutics is a favorable investment for most analysts.

What is Verve Therapeutics's price target?

Verve Therapeutics's price target, set by 12 Wall Street analysts, averages $14.5 over the next 12 months. The price target range spans from $14 at the low end to $15 at the high end, suggesting a potential 215.90% change from the previous closing price of $4.59.

How does Verve Therapeutics stock forecast compare to its benchmarks?

Verve Therapeutics's stock forecast shows a 215.90% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Verve Therapeutics over the past three months?

  • April 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Verve Therapeutics’s EPS forecast?

Verve Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.81, marking a 19.57% increase from the reported $-2.35 in 2024. Estimates for the following years are $-2.91 in 2026, $-2.9 in 2027, and $-3.38 in 2028.

What is Verve Therapeutics’s revenue forecast?

Verve Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $14.57M, reflecting a -54.95% decrease from the reported $32.33M in 2024. The forecast for 2026 is $9.98M, followed by $34M for 2027, and $13.6M for 2028.

What is Verve Therapeutics’s net income forecast?

Verve Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-189M, representing a -4.74% decrease from the reported $-199M in 2024. Projections indicate $-194M in 2026, $-187M in 2027, and $-217M in 2028.